MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of treatments Innovators, today announced three upcoming poster presentations at the IDWeek 2024 conference, taking place October 16-19 in Los Angeles, California.
One poster presents data linking excess abdominal visceral fat to increased risk of cardiovascular disease in people living with HIV, while a second poster informs how the use of tesamorelin, a Growth hormone releasing factor (GH-RF) analogue, to decrease excess abdominal visceral fat may reduce the risk of cardiovascular disease in people living with HIV. Another poster reports on the study design and initial characteristics of the PROMISE-US study, a real-world observational study of ibalizumab, a post-fixation HIV-1 antiretroviral directed against CD4, and carried out on patients who have received numerous treatments and whose infection is multi-drug resistant.
“The posters that will be presented at IDWeek highlight important medical issues that people living with HIV face,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. “As people live longer with HIV and have greater exposure to antiretroviral drugs, they may have increased excess abdominal visceral fat and risk of multidrug resistance. We look forward to sharing our findings with HIV clinicians and researchers at this premier infectious disease conference. »
Theratechnologies will present the following posters at the 2024 ID Week event:
Titre : Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis
- Main author: Steven Grinspoon, M.D., Massachusetts General Hospital et Harvard Medical School, Boston (Massachusetts).
- Date and time: Thursday, October 17, 2024, 12:15 p.m. – 1:30 p.m. (PST)
- Session title: HIV: Complications and Coinfections
- Lieu : Halls JK
- Billboard number: P-433
Titre : Cardiovascular Risk Scores and Insulin Resistance are Higher with Excess Visceral Abdominal Fat in People with HIV in the Modern Antiretroviral (ART) Era
- Presenting author: Karam Mounzer, M.D., University of Pennsylvania Perelman School of Medicine, Philadelphie (Pennsylvanie)
- Date and time: Thursday, October 17, 2024, 12:15 p.m. – 1:30 p.m. (PST)
- Session title: HIV: Complications and Coinfections
- Lieu : Halls JK
- Billboard number: P-453
Titre : A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics
- Presenting author: Charlotte-Paige Rolle, M.D., Orlando Immunology Center and Emory Rollins School of Public Health, Orlando (Floride)
- Date and time: Thursday, October 17, 2024, 12:15 p.m. – 1:30 p.m. (PST)
- Session title: HIV: Treatment
- Lieu : Halls JK
- Billboard number: P-565
IDWeek est la réunion annuelle conjointe de l’Infectious Diseases Society of America, de la Society for Healthcare Epidemiology of America, de la HIV Medicine Association, de la Pediatric Infectious Diseases Society et de la Society of Infectious Diseases Pharmacists.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative treatments that address unmet medical needs. For further information on Theratechnologies, you can consult the Company’s website at www.theratech.com/fr, on the SEDAR+ platform at www.sedarplus.ca or on the EDGAR database at address www.sec.gov. Follow Theratechnologies on LinkedIn and Twitter.
Forward-looking statements
This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. These forward-looking statements are based on the opinions and assumptions of management or on information available on the date they are made and are identified by the use of words such as “may”, “will”, “could”, ” would”, “should”, “promising”, “outlook”, “believes”, “plans”, “intends”, “forecasts”, “expects” and “estimates” or the negative of these terms or variations of these. Forward-looking statements contained in this press release include, but are not limited to, longevity in people living with HIV and its relationship to increased excess abdominal visceral fat and risk of multidrug resistance. Forward-looking statements are subject to a number of assumptions as well as several risks and uncertainties. The Company directs current and potential investors to refer to the “Risk Factors” section of its Form 20-F dated February 21, 2024, available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov in the documents filed by Theratechnologies. The reader is urged to consider these risks and uncertainties carefully and not place undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events. They are only valid as of the date of this press release and reflect the Company’s expectations on that date.
The Company undertakes no obligation to update or revise the information herein, whether as a result of new information, new events or circumstances or otherwise, unless applicable laws do so. ‘require.
Contacts:
Media inquiries:
Julie Schneiderman
Senior Director, Communications and Corporate Affairs
[email protected]
1 514 336-7800
Investor requests:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
[email protected]
438 315-6608
